The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Robert F. Kennedy Jr., nominated to be health secretary, seemed unfamiliar with the particulars of the massive insurance ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

Pharmaceutical executives are near unanimous (with 68% strongly agreeing and 31% somewhat agreeing) in their concern about a marked increase in theft, fraud, and/or attacks in the pharmaceutical ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.